These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25957418)

  • 1. Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.
    Bagdonaite I; Wandall HH; Litvinov IV; Nastasi C; Becker JC; Dabelsteen S; Geisler C; Bonefeld CM; Zhang Q; Wasik MA; Zhou Y; Sasseville D; Ødum N; Woetmann A
    Oncotarget; 2015 Jun; 6(16):14374-84. PubMed ID: 25957418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.
    Zhang Q; Wang HY; Wei F; Liu X; Paterson JC; Roy D; Mihova D; Woetmann A; Ptasznik A; Odum N; Schuster SJ; Marafioti T; Riley JL; Wasik MA
    J Immunol; 2014 Mar; 192(6):2913-9. PubMed ID: 24523507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.
    Engel P; Nojima Y; Rothstein D; Zhou LJ; Wilson GL; Kehrl JH; Tedder TF
    J Immunol; 1993 Jun; 150(11):4719-32. PubMed ID: 7684411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells.
    Naito-Matsui Y; Takada S; Kano Y; Iyoda T; Sugai M; Shimizu A; Inaba K; Nitschke L; Tsubata T; Oka S; Kozutsumi Y; Takematsu H
    J Biol Chem; 2014 Jan; 289(3):1564-79. PubMed ID: 24297165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reevaluation of CD22 expression in human lung cancer.
    Pop LM; Barman S; Shao C; Poe JC; Venturi GM; Shelton JM; Pop IV; Gerber DE; Girard L; Liu XY; Behrens C; Rodriguez-Canales J; Liu H; Wistuba II; Richardson JA; Minna JD; Tedder TF; Vitetta ES
    Cancer Res; 2014 Jan; 74(1):263-71. PubMed ID: 24395821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
    Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
    Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.
    Esmailzadeh S; Huang Y; Su MW; Zhou Y; Jiang X
    Leukemia; 2015 Jun; 29(6):1402-13. PubMed ID: 25578476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
    Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
    Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo.
    Haas KM; Sen S; Sanford IG; Miller AS; Poe JC; Tedder TF
    J Immunol; 2006 Sep; 177(5):3063-73. PubMed ID: 16920943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.
    Krejsgaard T; Vetter-Kauczok CS; Woetmann A; Kneitz H; Eriksen KW; Lovato P; Zhang Q; Wasik MA; Geisler C; Ralfkiaer E; Becker JC; Ødum N
    Blood; 2009 Jun; 113(23):5896-904. PubMed ID: 19351960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma.
    van Doorn R; Dijkman R; Vermeer MH; Starink TM; Willemze R; Tensen CP
    Cancer Res; 2002 Oct; 62(19):5389-92. PubMed ID: 12359741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions.
    Nakashima H; Hamaguchi Y; Watanabe R; Ishiura N; Kuwano Y; Okochi H; Takahashi Y; Tamaki K; Sato S; Tedder TF; Fujimoto M
    J Immunol; 2010 May; 184(9):4637-45. PubMed ID: 20335532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
    Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
    J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.
    Nitschke L
    Glycobiology; 2014 Sep; 24(9):807-17. PubMed ID: 25002414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.
    Tuscano JM; Kato J; Pearson D; Xiong C; Newell L; Ma Y; Gandara DR; O'Donnell RT
    Cancer Res; 2012 Nov; 72(21):5556-65. PubMed ID: 22986740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70.
    Ferenczi K; Ohtola J; Aubert P; Kessler M; Sugiyama H; Somani AK; Gilliam AC; Chen JZ; Yeh I; Matsuyama S; McCormick TS; Cooper KD
    Br J Dermatol; 2010 Sep; 163(3):564-71. PubMed ID: 20408834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
    Wu K; Lund M; Bang K; Thestrup-Pedersen K
    Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
    Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
    Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.